Clinical Trial Update: Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating pioglitazone to prevent recurrent myocardial infarction in patients with diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Myocardial Infarction

Drugs mentioned

• Actos (Pioglitazone)

Snippet

Sponsor: National Cerebral and Cardiovascular Center, Japan | Conditions: Diabetes Mellitus, Myocardial Infarction | Phase 4 | Status: TERMINATED